10x Genomics, Inc. TXG R2KR3KPHARMA
Company Overview
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Why Investors Should Care
Revenue has grown at a 31.7% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.10.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $642.82M (+5.2% YoY); net profit $-43.54M.
- Trailing 12 Months Year-on-year growth — revenue -2.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 31.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 31.69% |
| 1 Year: | -2.60% |
Stock Price Performance
| 1 Year: | +361.68% |
| 6 Months: | +201.06% |
| 3 Months: | +101.84% |
| 1 Month: | +37.39% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)60.90 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 31.7% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TXG 10x Genomics, Inc. R2KR3KPHARMA | 62.65 | -106.19 | $7.32B | 0.00% | -6.87% | -2.98% | 31.69% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 55.82M | 61.21M | - | 71.91M | 42.91M | 71.82M | 105.82M | 115.84M | 125.30M | 114.50M | 114.61M | 131.07M | 134.28M | 146.82M | 153.64M | 141.01M | 153.10M | 151.65M | 154.88M | 172.91M | 149.00M | 150.84M | 151.04M |
| Gross Profit | 23.44M | 27.19M | 31.37M | 35.65M | 39.61M | 40.81M | 45.73M | 58.71M | 56.80M | 32.85M | 57.41M | 88.76M | 110.93M | 100.78M | 89.02M | 86.91M | 100.69M | 98.39M | 99.61M | 95.53M | 92.91M | 104.22M | 106.39M | 105.44M | 125.08M | 100.31M | 106.18M | 112.50M |
| Operating Income | - | - | -14.93M | - | -3.04M | -10.36M | -9.10M | - | -19.88M | -39.42M | -65.25M | -10.22M | -10.33M | -15.88M | -41.73M | -63.12M | -40.00M | -51.99M | -63.36M | -94.80M | -61.50M | -41.74M | -41.48M | -39.33M | 30.13M | -32.24M | -17.05M | -19.55M |
| Net Income | -15.69M | -5.92M | -15.35M | -75.52M | -3.64M | -10.88M | -9.60M | -7.13M | -21.14M | -40.17M | -65.85M | -11.55M | -11.05M | -17.17M | -42.41M | -64.46M | -41.91M | -50.75M | -62.41M | -92.99M | -59.95M | -37.90M | -35.75M | -34.36M | 34.54M | -27.47M | -13.47M | -17.93M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.22 | -0.41 | -0.65 | -0.11 | -0.10 | -0.15 | -0.38 | -0.57 | -0.37 | -0.44 | -0.53 | -0.79 | -0.50 | -0.32 | -0.30 | -0.28 | 0.28 | -0.22 | -0.10 | -0.14 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 71.08M | 146.31M | 245.89M | 298.85M | 490.49M | 516.41M | 618.73M | 610.78M | 642.82M |
| Gross Profit | 60.52M | 117.65M | 184.86M | 240.38M | 416.40M | 396.02M | 409.31M | 414.48M | 443.88M |
| Operating Income | -18.38M | -110.76M | -30.57M | -534.14M | -52.25M | -167.94M | -265.33M | -194.56M | -60.98M |
| Net Income | -18.76M | -112.48M | -31.25M | -542.73M | -58.22M | -166.00M | -255.10M | -182.63M | -43.54M |
| Diluted EPS | - | - | -0.80 | -5.37 | -0.53 | -1.46 | -2.18 | -1.52 | -0.35 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jan 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 124.31M | 605.92M | 45.60M | 929.34M | 1.02B | 1.03B | 965.14M | 918.64M | 1.04B |
| Total Equity | -96.43M | -112.51M | -219.99M | 420.08M | - | 739.07M | 817.57M | 805.74M | 741.04M | 710.13M | 796.33M |
| Cash & Equivalents | - | 47.86M | 65.08M | 424.17M | - | 663.60M | 587.45M | 219.75M | 359.28M | 344.07M | - |
| Long Term Debt | - | - | 25.49M | 19.84M | - | 0 | - | - | - | - | - |
| Total Liabilities | - | - | 101.05M | 185.84M | 78.14M | 190.27M | 201.26M | 223.24M | 224.10M | 208.50M | 245.04M |
| Current Liabilities | - | - | 32.36M | 63.05M | - | 118.13M | 110.36M | 130.96M | 127.16M | 117.63M | 153.45M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -10.70M | -76.41M | 34.63M | -217.90M | -21.37M | -33.61M | -15.20M | 6.66M | 136.05M |
| Investing Cash Flow | -3.76M | -6.71M | -42.77M | -38.39M | -106.73M | -350.89M | 133.49M | -32.63M | -13.44M |
| Financing Cash Flow | 20.58M | 105.37M | 414.59M | 468.91M | 35.30M | 15.82M | 13.67M | 10.91M | 6.80M |
| Capital Expenditure | -3.76M | -6.28M | -42.74M | -36.67M | -101.28M | -131.66M | -48.60M | -12.39M | -5.93M |
| Free Cash Flow | -14.46M | -82.69M | -8.12M | -254.56M | -122.65M | -165.27M | -63.80M | -5.73M | 130.12M |
| Share Buybacks | 80.00K | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 85.1% | 80.4% | 75.2% | 80.4% | 84.9% | 76.7% | 66.2% | 67.9% | 69.1% |
| Operating Margin % | -25.8% | -75.7% | -12.4% | -178.7% | -10.7% | -32.5% | -42.9% | -31.9% | -9.5% |
| Net Margin % | -26.4% | -76.9% | -12.7% | -181.6% | -11.9% | -32.1% | -41.2% | -29.9% | -6.8% |
| ROE % | 16.7% | 51.1% | -7.4% | -73.4% | -7.1% | -20.6% | -34.4% | -25.7% | -5.5% |
| ROCE % | - | -120.5% | -5.6% | -65.8% | -5.8% | -18.7% | -31.7% | -24.3% | -6.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.67% | 17.63M | $1.08B |
| 2 | Blackrock Inc. | 8.99% | 10.80M | $664.88M |
| 3 | ARK Investment Management, LLC | 8.32% | 10.00M | $615.59M |
| 4 | Vanguard Portfolio Management LLC | 5.81% | 6.98M | $429.70M |
| 5 | Quantinno Capital Management, LP | 4.55% | 5.47M | $336.61M |
| 6 | Vanguard Capital Management LLC | 4.23% | 5.08M | $312.78M |
| 7 | Price (T.Rowe) Associates Inc | 3.78% | 4.54M | $279.33M |
| 8 | Sumitomo Mitsui Trust Group, Inc. | 3.49% | 4.19M | $258.14M |
| 9 | Amova Asset Management Americas Inc | 3.49% | 4.19M | $258.01M |
| 10 | Morgan Stanley | 2.79% | 3.35M | $206.28M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TXG
TXG Stock Price and Chart — NASDAQ:TXG - TradingView
<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE5qMmlvbTRDQjNlVEtKQWhOMVByc2hrU2dvalVWSnliaDZRWGN5ekhjUEIzaXYyZlpLM2d0UFNEUnRJeVRDZy1zcU1XUzdDQXZkTlNCUjhMRko4Y3M?oc=5" target="_blank">TXG Stock Price and Chart — NASDAQ:TXG</a>&n…
TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPdEUwRmQtbTBScEZUZkRBdGVBbHA2UVZhdDdQTjM5RXhfM2p0NEJFaUtYancxQVpKQ1Q1bUlNNWhGbDFDN3BiY2FFb2VCSkdGNjhhVTZXMkNYUmpyaWNhNFF6eUhkajI2RU9sbXVSRGwzcDkzSHh6VnhvZ19FWi10OGZ1VXB1RGNZX0tYaH…
10x Genomics (TXG) CEO holds 1,075,249 shares after 100-share gift - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPRnFnV1dmekQybjZFbURvaXJKSnZGWndZaTNxZldZWW9PRjZSX0NFa1dDOEp1WC1FcHozVWE0akFpZUhTYldlWGNxRkFlRXdDOVp2c2t4NEtlMGNxLVRNdEhuR1pkdG9LRTB4Ym5rVUVhbU95MGRkNlVSY25IRlRQZWFHS3d3dFVONklPaV…
10x Genomics (TXG) Could Be 27% Below Fair Value On Raised 2026 Guidance - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxPNFZRY3dFd0hVbzNmVFQxdS1pZzFlVXloellYZzFVc0hFX1JwMXRQRFF1blVBblRwMlFHX3A0X0RwLU81eVpNM1Y4d1lwYkFxbWhRNzF3ZUd3dDlQTVdENFVFRE5CaFU1S29uUkVoeUJjYVgxZjBXQUdHNGZkWGVJakNOdmdRWnQ3TFR3WH…
10x Genomics: The Turnaround Is Real, But Atera Now Has To Deliver (Rating Upgrade) (TXG) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOMDBTYllPalRlLVozTFlGZzhYSER2d3phYnd0VW84c2J3SzlqNDJrSmxyZVhiaDd5M2hVdmkyRmdvZ0xMQnE3WGpXMm02VlNmWUY5WjBUZkx5MWEtYzQ0bWlqM29RcS1pcEpoLU9CdXpDLS1EamFLVkNpNE40NE1iMzJkandDbk1sb2JxUC…
Why 10x Genomics (TXG) Stock Is Down Today - StockStory
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNVGVkaDZ2emhIXzdrM1ZLRDBHYjhqV3d2ZUNYcUxVUFpDcDEwUTBJV2Y5dWtRSnhIRmxiYXhiSTlVYzVFczRsWDdhblh4TmRZYkVGX3RKQVJ4X252Wl9OMEtxZTNBbmRJLXh0V1NMa3NpNWYzOHA5NHFnaHUyWlk0aHRKLWdQTGhLeTRSZy…
TXG — Frequently Asked Questions
What is the current share price of 10x Genomics, Inc. (TXG)?
As of 2026-09-07 16:24 PDT, 10x Genomics, Inc. (TXG) trades at $62.65 on NasdaqGS. Its 52-week range is $11.34 to $65.12.
What is the market capitalisation of TXG?
10x Genomics, Inc. (TXG) has a market capitalisation of $7.32B on NasdaqGS.
What is the P/E ratio of TXG?
TXG trades at a trailing price-to-earnings (P/E) ratio of -106.19. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 8.24.
What is the return on equity (ROE) of TXG?
TXG has a return on equity (ROE) of -2.98%. Its return on capital employed (ROCE) is -6.87%.
Is TXG a good stock to buy?
This page provides a data-driven analysis of 10x Genomics, Inc. (TXG), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.